1356483-62-9Relevant academic research and scientific papers
Discovery of benzimidazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys
Hoyt, Scott B.,Park, Min K.,London, Clare,Xiong, Yusheng,Tata, Jim,Bennett, D. Jonathan,Cooke, Andrew,Cai, Jiaqiang,Carswell, Emma,Robinson, John,MacLean, John,Brown, Lindsay,Belshaw, Simone,Clarkson, Thomas R.,Liu, Kun,Liang, Gui-Bai,Struthers, Mary,Cully, Doris,Wisniewski, Tom,Ren, Ning,Bopp, Charlene,Sok, Andrea,Cai, Tian-Quan,Stribling, Sloan,Pai, Lee-Yuh,Ma, Xiuying,Metzger, Joe,Verras, Andreas,McMasters, Daniel,Chen, Qing,Tung, Elaine,Tang, Wei,Salituro, Gino,Buist, Nicole,Kuethe, Jeff,Rivera, Nelo,Clemas, Joe,Zhou, Gaochao,Gibson, Jack,Maxwell, Carrie Ann,Lassman, Mike,McLaughlin, Theresa,Castro-Perez, Jose,Szeto, Daphne,Forrest, Gail,Hajdu, Richard,Rosenbach, Mark,Ali, Amjad
, p. 573 - 578 (2015)
We report the discovery of a benzimidazole series of CYP11B2 inhibitors. Hit-to-lead and lead optimization studies identified compounds such as 32, which displays potent CYP11B2 inhibition, high selectivity versus related CYP targets, and good pharmacokin
ALDOSTERONE SYNTHASE INHIBITORS
-
Page/Page column 41-42, (2012/02/05)
The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.
